Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Immunohistochemical analy… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Kontaktformulär








 


OBS! Vill du ha svar, ange e-post eller telefonnummer!




Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas

Artikel i vetenskaplig tidskrift
Författare A. M. do Canto
Bmrd Marcelino
J. L. Schussel
B. F. Wastner
L. M. Sassi
L. Correa
R. R. de Freitas
Bengt Hasséus
Göran Kjeller
C. A. Lemos
P. H. Braz-Silva
Publicerad i Clinical Oral Investigations
Volym 23
Nummer/häfte 2
Sidor 779-784
ISSN 1432-6981
Publiceringsår 2019
Publicerad vid Institutionen för odontologi
Sidor 779-784
Språk en
Länkar dx.doi.org/10.1007/s00784-018-2494-...
Ämnesord Ameloblastoma, Odontogenic tumours, Jaw, Immunohistochemistry, BRAFV600E mutation, Dentistry, Oral Surgery & Medicine
Ämneskategorier Odontologi

Sammanfattning

ObjectiveThis study aimed to investigate the presence of BRAF V600E mutation in mandible ameloblastomas by correlating clinical and imaging data on the cases studied.MethodsEighty-four cases diagnosed as mandibular ameloblastoma were selected for analysis. The specimens were submitted to immunohistochemistry for detection of BRAF V600E mutated protein. Clinical-pathological data such as age, gender, tumour size, mandibular location, radiographic aspects, histological type and sub-type, and tumour status were collected. The clinical-pathological parameters were categorised and analysed according to BRAF V600E detection.ResultsOf the 84 patients, 78.6% (66 cases) demonstrated positivity for anti-BRAF V600E antibody, whereas 18 were negative (21.4%). The correlation between BRAF expression and variables showed statistical significances for mandibular location (P=0.0353) and tumour size (P=0.008), whereas no statistical significance was observed for gender, age, radiographic aspect, histological pattern, histological sub-type and tumour status. Multivariate logistic regression revealed a significant risk for BRAF positivity in tumours with posterior mandibular location (OR=7.23, P=0.0451) and size >4cm (OR=7.29, P=0.0150).ConclusionBRAF V600E mutation is common in mandibular ameloblastomas, especially in cases of tumours larger than 4cm and in the posterior region of the mandible. In addition, this mutation can occur regardless of histological type of the tumour, age, gender, radiographic aspect and tumour status.Clinical significanceThe association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia. The use of BRAF inhibitors for targeted therapy could lead to an establishment of an alternative compared to the resective surgery.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?

Denna text är utskriven från följande webbsida:
http://www.gu.se/forskning/publikation/?feedbackForm=true&returnAddress=http%3A%2F%2Fwww.gu.se%2Fforskning%2Fpublikation%2F%3FpublicationId%3D278137&recipientName=Webbredaktion&encodedEmail=aW5mb0BndS5zZQ&publicationId=278137
Utskriftsdatum: 2019-11-12